BioStock: Positive results for RhoVac in 3-year follow-up of phase I/II-study
The results speak for themselves when RhoVac presents its follow-up of the phase I/II study conducted three years ago at Rigshospitalet in Copenhagen. No metastases, no indication of a need for further treatment in order to maintain immunity, and no indication of significant development of PSA in treated patients. This is great news for the company, says CEO Anders Månsson when BioStock contacts him.
Read the full article at biostock.se:
https://www.biostock.se/en/2021/10/positive-results-for-rhovac-in-3-year-follow-up-of-phase-i-ii-study/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se